Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 4
1993 3
1994 4
1995 8
1996 6
1997 5
1998 13
1999 27
2000 42
2001 41
2002 72
2003 83
2004 70
2005 91
2006 74
2007 72
2008 89
2009 63
2010 69
2011 71
2012 91
2013 75
2014 83
2015 70
2016 77
2017 57
2018 52
2019 59
2020 66
2021 56
2022 64
2023 51
2024 65
2025 47

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,658 results

Results by year

Filters applied: . Clear all
Page 1
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E, Toumi H. Lespessailles E, et al. Int J Mol Sci. 2022 Sep 14;23(18):10733. doi: 10.3390/ijms231810733. Int J Mol Sci. 2022. PMID: 36142643 Free PMC article. Review.
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole). Recently, the risks and benefits of long-term PPI use were questioned and many studies indicated that their use should …
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and …
Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Ochoa D, Román M, Cabaleiro T, Saiz-Rodríguez M, Mejía G, Abad-Santos F. Ochoa D, et al. BMC Pharmacol Toxicol. 2020 Jul 25;21(1):54. doi: 10.1186/s40360-020-00433-2. BMC Pharmacol Toxicol. 2020. PMID: 32711578 Free PMC article. Clinical Trial.
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clinical trials. METHOD: Subjects were evaluated to determine the …
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study popu …
Pharmacological treatment of gastro-oesophageal reflux in children.
Tighe MP, Andrews E, Liddicoat I, Afzal NA, Hayen A, Beattie RM. Tighe MP, et al. Cochrane Database Syst Rev. 2023 Aug 22;8(8):CD008550. doi: 10.1002/14651858.CD008550.pub3. Cochrane Database Syst Rev. 2023. PMID: 37635269 Free PMC article.
Children Proton pump inhibitors (PPIs) at different doses may provide little to no symptomatic and endoscopic benefit. Rabeprazole given at different doses (0.5 mg/kg and 1 mg/kg) may provide similar symptom improvement (127 children in total; very low-certainty evidence). …
Children Proton pump inhibitors (PPIs) at different doses may provide little to no symptomatic and endoscopic benefit. Rabeprazole gi …
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Çelebi A, et al. Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514. Turk J Gastroenterol. 2016. PMID: 27782887 Free article. Clinical Trial.
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was found to have the most rapid action, followed by lansoprazole …
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time …
Effectiveness of Rabeprazole and Other Proton Pump Inhibitors in Managing GERD with Varying Severity: A Retrospective, Real-world EMR-based Study (POWER GERD Study).
Lawate P, Jilawar N, Vyas K, Pebbili KK, Desai S, Rathod R, Kotak B, Paspulate A. Lawate P, et al. J Assoc Physicians India. 2023 Oct;71(10):37-44. doi: 10.59556/japi.71.0366. J Assoc Physicians India. 2023. PMID: 38716522
Conclusion: Rabeprazole was effective in providing quick and sustained relief for both daytime and nocturnal GERD symptoms in patients with moderate and severe GERD. Rabeprazole also demonstrated greater effectiveness when compared with pantoprazole and esomeprazole …
Conclusion: Rabeprazole was effective in providing quick and sustained relief for both daytime and nocturnal GERD symptoms in patient …
Rabeprazole: A comprehensive profile.
Bakheit AH, Al-Kahtani HM, Albraiki S. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:137-183. doi: 10.1016/bs.podrm.2020.07.003. Epub 2020 Aug 13. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461697
Rabeprazole belongs to the class of anti-secretory drugs, with benzimidazoles substitution. ...This chapter includes a comprehensive review of rabeprazole in terms of nomenclature, its physical-chemical properties, methods of preparation and ADME profiles. ...
Rabeprazole belongs to the class of anti-secretory drugs, with benzimidazoles substitution. ...This chapter includes a comprehensive …
Rabeprazole mitigates obesity-induced chronic inflammation and insulin resistance associated with increased M2-type macrophage polarization.
Li Y, Hao J, Kong X, Yuan W, Shen Y, Hui Z, Lu X. Li Y, et al. Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167142. doi: 10.1016/j.bbadis.2024.167142. Epub 2024 Mar 31. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 38565384 Free article.
Macrophage polarization is closely associated with obesity-induced chronic inflammation and insulin resistance. Proton pump inhibitor Rabeprazole has long been used to treat gastritis and gastric ulcers. However, whether Rabeprazole plays a role in macrophage polari …
Macrophage polarization is closely associated with obesity-induced chronic inflammation and insulin resistance. Proton pump inhibitor Rab …
Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Han YY, Zhou L, Hu YL, Ding XW, Long H, Liu F, Xu M, Zhang ZY, Li SL, Wang QY, Su CX, Chen Y, Chen J, Lin Y, Li PY. Han YY, et al. J Gastroenterol. 2023 Dec;58(12):1167-1177. doi: 10.1007/s00535-023-02042-2. Epub 2023 Oct 1. J Gastroenterol. 2023. PMID: 37777987 Clinical Trial.
This study aimed to compare efficacy and safety of the 10-day vonoprazan-amoxicillin (VA) and 14-day rabeprazole-amoxicillin (RA) dual therapy, and to provide a more efficient, safer, and convenient dual regimen for H. pylori infection. ...The participants were randomly as …
This study aimed to compare efficacy and safety of the 10-day vonoprazan-amoxicillin (VA) and 14-day rabeprazole-amoxicillin (RA) dua …
Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Dash RP, Rais R, Srinivas NR. Dash RP, et al. Xenobiotica. 2018 Apr;48(4):422-432. doi: 10.1080/00498254.2017.1307470. Epub 2017 Apr 6. Xenobiotica. 2018. PMID: 28294690 Review.
Despite having a high degree of structural resemblance, rabeprazole, was shown to possess some unique differentiation from other drugs in the class. ...The review was aimed to provide pharmacokinetic data of rabeprazole from several clinical studies including drug-d …
Despite having a high degree of structural resemblance, rabeprazole, was shown to possess some unique differentiation from other drug …
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Barberio B, Visaggi P, Savarino E, de Bortoli N, Black CJ, Ford AC. Barberio B, et al. Neurogastroenterol Motil. 2023 Jan;35(1):e14469. doi: 10.1111/nmo.14469. Epub 2022 Sep 25. Neurogastroenterol Motil. 2023. PMID: 36153790 Free PMC article.
(P-score 0.94) ranked first, with esomeprazole 20 mg o.d. or 40 mg o.d. ranked second and third. In achieving adequate relief, only rabeprazole 10 mg o.d. was significantly more efficacious than placebo. For failure to achieve complete relief at 4 weeks, dexlansoprazole 30 …
(P-score 0.94) ranked first, with esomeprazole 20 mg o.d. or 40 mg o.d. ranked second and third. In achieving adequate relief, only rabep …
1,658 results